274 related articles for article (PubMed ID: 34555481)
1. A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Mazur R; Ghelani P; Forrer P; Wraith L; Patekar M
J Am Acad Dermatol; 2022 Jan; 86(1):122-130. PubMed ID: 34555481
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Sticherling M; Nikkels AF; Hamza AM; Kwong P; Szepietowski JC; El Sayed M; Ghislain PD; Khotko AA; Patekar M; Ortmann CE; Forrer P; Papanastasiou P; Keefe D
Am J Clin Dermatol; 2023 Sep; 24(5):821-835. PubMed ID: 37341961
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.
Bodemer C; Kaszuba A; Kingo K; Tsianakas A; Morita A; Rivas E; Papanastasiou P; Keefe D; Patekar M; Charef P; Zhang L; Cafoncelli S; Papavassilis C
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):938-947. PubMed ID: 33068444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C
Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
Blair HA
Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Cai L; Zhang JZ; Yao X; Gu J; Liu QZ; Zheng M; Zhang SF; Xu JH; Li CX; Cheng H; Guo Q; Pan WL; Li SQ; Li RY; Guo ZP; Song ZQ; Li SS; Dong XQ; Wang L; Fu R; Regnault P; Charef P; Mazur R; Patekar M
Chin Med J (Engl); 2020 Nov; 133(22):2665-2673. PubMed ID: 33060370
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE).
Warren RB; Barker JNWB; Finlay AY; Burden AD; Kirby B; Armendariz Y; Williams R; Hatchard C; Khare S; Griffiths CEM
Br J Dermatol; 2020 Jul; 183(1):60-70. PubMed ID: 31628677
[TBL] [Abstract][Full Text] [Related]
19. Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.
Chen XB; Zheng YX; Ye LR; Chen XY; Man XY
Dermatol Ther; 2022 Dec; 35(12):e15911. PubMed ID: 36209377
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
